Mirati Therapeutics, Inc.

MRTX · NASDAQ
Analyze with AI
9/30/2023
6/30/2023
3/31/2023
12/31/2022
Operating Activities
Net Income-$162-$177-$185-$202
Dep. & Amort.$1$1$1$1
Deferred Tax-$122-$144$0$0
Stock-Based Comp.$45$39$47$62
Change in WC-$23$12-$49$17
Other Non-Cash$117$138-$5-$6
Operating Cash Flow-$144-$131-$190-$129
Investing Activities
PP&E Inv.-$0-$1-$0-$1
Net Acquisitions$62-$16-$195-$60
Inv. Purchases-$342-$237-$127-$237
Inv. Sales/Matur.$280$253$322$297
Other Inv. Act.-$62$16$195$60
Investing Cash Flow-$62$16$195$59
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$329$3$2$155
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$335$4$2$6
Financing Cash Flow$335$4$2$6
Forex Effect$0-$0-$0$0
Net Chg. in Cash$129-$112$7-$64
Supplemental Information
Beg. Cash$130$243$236$299
End Cash$259$130$243$236
Free Cash Flow-$144-$132-$190-$130
Mirati Therapeutics, Inc. (MRTX) Financial Statements & Key Stats | AlphaPilot